Drug Trial Radar · NCT02879305
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,964
Actual
Start
Sep 28, 2016
Primary completion
Nov 9, 2020
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
Conditions
- Anaemia
- Aspergillosis, Allergic Bronchopulmonary
Interventions
DaprodustatDrug
Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
rhEPODrug
The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
PlaceboDrug
Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Iron therapyDrug
Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority AnalysisTime frame: Up to 3.9 person-years for CV follow-up time period
- Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Locations
462 sites in 35 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Pine Bluff, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
El Centro, California
GSK Investigational Site
Escondido, California
GSK Investigational Site
Fairfield, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Glendale, California
GSK Investigational Site
Granada Hills, California
GSK Investigational Site
Hacienda Heights, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
La Palma, California
GSK Investigational Site
Lakewood, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Lynwood, California
GSK Investigational Site
Montebello, California
GSK Investigational Site
Monterey Park, California
GSK Investigational Site
Moreno Valley, California
GSK Investigational Site
Norco, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Ontario, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Luis Obispo, California
GSK Investigational Site
Santa Clarita, California
GSK Investigational Site
Simi Valley, California
GSK Investigational Site
Tarzana, California
GSK Investigational Site
Whittier, California
GSK Investigational Site
Whittier, California
Showing 40 of 462 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.